Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AdimrSC-2f COVID-19 Vaccine in Healthy Volunteers
NCT04522089Phase 1Completed
- Sponsor
- Adimmune
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AdimrSC-2f in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Adimmune. Primary endpoints: Solicited Adverse Events (SoAEs) and Incidence of Abnormal Laboratory Tests Results. Started Aug 2020; status: completed.
02
Drugs
AdimrSC-2f
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04522089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522089.